Asklepios BioPharmaceuticals has stated that it intends to start phase-in clinical trials of LION-101 in the first half of 2022
The FDA has approved a new drug research program (IND) for Asklepios BioPharmaceutical LION-101, a research gene therapy for the treatment of LGMD2I / R9 limb girdle muscular dystrophy. Therefore, the company is pursuing a phase 1/2 clinical study.